Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio and expanding international operations. Globa
Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Moby summary of Evolus, Inc.'s Q1 2026 earnings call
Evolus (NASDAQ:EOLS) reported first-quarter results that management said reflected a stronger operating model following cost structure changes implemented last year, while reiterating its full-year 2026 outlook for double-digit revenue growth and adjusted EBITDA profitability. First-quarter results
David Moatazedi: Thank you, Nareg, and good afternoon, everyone. Internationally, the business continues to deliver strong performance and is increasingly contributing to our growth trajectory as we expand our global footprint in key markets.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.